分类： health

In the conflict-wracked eastern region of the Democratic Republic of the Congo, a devastating Ebola outbreak driven by the rare Bundibugyo virus has reached a grim milestone, with confirmed cases climbing to 2,011 and total deaths hitting 754, according to newly released official government data. World Health Organization (WHO) officials confirm this is the fastest-expanding Ebola event ever recorded, outpacing containment efforts at every turn.

The crisis has been compounded by growing unrest among frontline medical teams, who have walked off the job over unmet pay promises. On Wednesday, staff at Bunia General Hospital — the largest medical facility in the outbreak’s epicenter — launched a strike, barricading the hospital entrance to demand long-delayed wages earned while working in high-risk, resource-strapped conditions. This industrial action follows a similar strike just two days earlier at an Ebola treatment center in Rwampara, another Ituri Province hotspot that has borne the brunt of the outbreak. That strike ended after workers secured a government commitment to issue back pay within 72 hours, but many frontline staff report they have not received any compensation since the outbreak began in mid-May, leaving deep lingering frustration.

Public health experts warn multiple overlapping barriers are making the outbreak extremely difficult to contain. The most pressing issue is the unprecedented rate of spread: roughly 80% of all new confirmed cases stem from unknown transmission chains that officials have been unable to map. To date, authorities have only successfully traced 67% of known close contacts of infected patients, a rate far too low to halt transmission. Complicating tracing efforts further, health teams have still not identified the outbreak’s index case (patient zero), while widespread population displacement from ongoing armed conflict and frequent cross-community movement of artisanal miners have scattered thousands of potentially exposed people across the region.

Unlike previous Ebola outbreaks in Congo that were caused by the more common Zaire strain — for which effective, approved vaccines and treatments already exist — there are no licensed medical countermeasures for the Bundibugyo virus driving this current event. In a small glimmer of hope for the response, enrollment for a clinical trial testing two promising investigational treatments has recently launched in Ituri, though results will not be available for months.
Additional systemic challenges continue to undermine response work: a critical funding gap has left operations under-resourced, repeated attacks on health facilities have forced care closures in high-risk areas, ongoing armed violence in eastern Congo prevents teams from reaching remote communities, and deep-seated mistrust between local populations and public health workers has reduced cooperation with contact tracing and isolation efforts.
As of the latest data release, 753 patients remain in isolation care at hospitals across the region, while 366 people have recovered from infection so far. More than 100 frontline healthcare workers have already contracted the virus since the outbreak began, according to WHO figures. WHO’s emergencies chief Dr. Chikwe Ihekweazu, who recently completed an assessment visit to Bunia, noted that many of the newly recorded deaths are people who never accessed care, dying in their home communities before medical teams could intervene.

In the sweltering hills of central Cameroon, Mabel Djoumessi trekked for miles along rain-soaked, mud-caked dirt roads, her 9-month-old son Kenfack strapped securely to her back. Her destination: a local clinic, where Kenfack was scheduled for his malaria vaccine — an appointment too urgent to skip, even in poor conditions.

For generations, malaria has reigned as one of the deadliest threats to young children across the African continent, leaving millions of families grappling with repeated sickness and unmanageable medical costs. Today, Kenfack has never contracted the disease, a outcome his mother credits directly to the new malaria vaccine that has entered routine childhood immunization schedules across the country. “My other children, who never had access to the vaccine, get sick all the time,” Djoumessi explained, as she sat alongside other mothers holding their infants at Soa District Hospital.

It has now been more than two years since Cameroon made history as the first nation to integrate the RTS,S malaria vaccine into its standard routine immunization program, and frontline health workers are already documenting clear public health gains: severe malaria cases among children have dropped noticeably, and pediatric hospital wards that once overflowed with sick young patients are now far emptier. But a critical gap threatens to undermine these hard-won gains: too few families are returning for the fourth and final booster dose that the World Health Organization (WHO) confirms is essential to sustaining long-term immunity against the parasite.

This low fourth-dose coverage is not an isolated challenge limited to Cameroon. It reflects a systemic issue that plagues multidose vaccine rollouts across the entire African continent, where barriers ranging from travel costs to competing work and childcare responsibilities keep families from returning for follow-up doses months after the initial rounds of vaccination.

Global public health data underscores just how high the stakes are: the WHO and UNICEF estimate that malaria kills one child under the age of five every single minute worldwide, with more than 90% of those deaths occurring in Africa. Cameroon alone is among 11 nations that bear roughly 70% of the world’s total malaria burden; the country recorded an estimated 7.6 million cases and 11,700 deaths from the disease in 2024. Early 2025 data from Cameroon’s National Malaria Control Program shows a 33,000-drop in cases compared to the previous year, though experts caution that the vaccine is not the sole driver of this decline.

“Isolating the specific impact of malaria interventions requires advanced statistical modeling, and we do not yet have a framework to quantify the vaccine’s exclusive contribution,” explained Dr. Bomba Amougou, head of prevention at the National Malaria Control Program. “It is accurate to say the vaccine has contributed to falling cases and deaths, but it is not the only cause.”

The WHO first endorsed broad use of the RTS,S vaccine in 2021, after multi-year pilot programs in Ghana, Kenya and Malawi found the shot cut child mortality from malaria by 13% among eligible children. Separate clinical trials across several African nations found that both RTS,S and the newer R21 vaccine reduced clinical malaria cases by more than 50% in the first year after three doses. To date, more than 52 million doses have been delivered to 25 high-risk African nations, supported by Gavi, the Vaccine Alliance. But the rollout faces major funding constraints following sweeping cuts to foreign aid from the Trump administration and other donors. Currently, Gavi is only able to guarantee vaccine supplies to cover up to 70% of eligible children in the world’s lowest-income countries.

In Cameroon, coverage for the first three doses of the vaccine — given at six, seven, and nine months of age — has slowly improved since the program launched, climbing from 66% to 68% for first doses, 53% to 58% for second doses, and 48% to 59% for third doses between 2024 and 2025, according to Amougou. But coverage for the fourth dose, scheduled when a child turns two years old, remains stuck at just 25% as of 2025.

Amougou noted that gaps stem from both parent and provider awareness issues: “Parents and even some health workers sometimes forget the fourth dose, particularly because it is administered more than a year after the third, and this is still a relatively new vaccine.” Receiving all four doses is critical, he emphasized: “Getting every shot makes the protection far more potent, and vaccination must work alongside other tools like bed nets, early treatment, and improved sanitation to beat malaria.”

Data from the earlier pilot programs across Ghana, Kenya and Malawi confirms that the low fourth-dose coverage problem is widespread. While 80% of eligible children received their first dose in those countries, coverage dropped to just 46% for the fourth dose, according to a 2024 study published in the peer-reviewed Malaria Journal. Researchers found that high parent acceptance of the vaccine itself — driven by widespread familiarity with malaria’s deadly toll — but barriers like transport costs, lack of appointment reminders, poor care follow-up, and competing work and family obligations keep families from returning for the final booster months later.

Gavi Chief Executive Officer Dr. Sania Nishtar emphasized that low late-dose coverage is an early, solvable challenge that should not overshadow the vaccine’s life-saving value. Nishtar noted that malaria vaccine actually has the lowest rate of parental hesitancy of any routine vaccine, a reflection of how desperate communities are for tools to protect their children from a preventable killer. “There is huge demand from governments and communities for this vaccine,” she said.

In response to the coverage gap, Cameroon and other affected African nations have launched national “Big Catch-up” campaigns to remind parents and health workers to prioritize the fourth dose and bring eligible children who have missed their booster in for vaccination. Looking ahead, global health researchers are actively developing a single-dose malaria vaccine, which would eliminate the need for multiple follow-up visits and dramatically improve coverage. “The fewer the doses of a vaccine to be administered, the higher the uptake and the easier the administration,” Nishtar explained.

For many low-income families across Cameroon, preventing malaria is not just a matter of child health — it is also a matter of financial survival. Georgette Caroline Mengbwa, a mother of three waiting for her youngest daughter’s third dose at Soa District Hospital, explained that her two older children were born before the vaccine was available, and face repeated bouts of sickness that drain the family’s limited income. “They fall ill every two or three months, and I have to spend between $53 and $107 every time one or all of them get sick,” she said. “It’s a lot of money.” Those costs are devastating in a country where the official monthly minimum wage is just $76, and nearly 40% of the population lives below the poverty line.

For mothers like Djoumessi, the vaccine is already a life-changing tool, and she says she has every intention of returning for Kenfack’s fourth dose when he turns two. “I don’t want him to suffer like the others,” she said.

GENEVA — The World Health Organization’s top emergencies official issued a stark warning Tuesday, stating that the ongoing Ebola outbreak in the eastern region of the Democratic Republic of the Congo is still moving faster than international and local response teams can contain, following a firsthand assessment trip to one of the crisis’s hardest-hit areas. Chikwe Ihekweazu, WHO’s emergencies chief, returned this week from Bunia, located in Ituri province, the epicenter of the current outbreak, where he uncovered deeply troubling trends driving the virus’s spread.

According to Ihekweazu, the most worrying observation from his visit is that a large share of newly reported fatalities are people who never accessed formal medical care, passing away in their home communities before they could reach a treatment facility. As of this week, he added, roughly 80 percent of all new confirmed cases are not linked to existing contact tracing lists, meaning they originate from unknown transmission chains that response teams have not been able to track or pre-empt.

The DRC has been fighting this outbreak of the rare Bundibugyo Ebola variant since undetected community transmission began in early May, with no approved vaccine or specific antiviral treatment currently available for this strain. The Africa Centres for Disease Control and Prevention labeled the event the fastest-expanding Ebola outbreak the African continent has ever seen last week.

Congolese health authorities released updated figures Monday showing at least 1,926 confirmed and probable infections across three affected provinces, with a total of 702 recorded deaths. The outbreak has already spilled across national borders, with confirmed cases detected in neighboring Uganda, raising concerns of a wider regional spread. Last week, the U.S. Centers for Disease Control and Prevention announced that a U.S. citizen working for a humanitarian organization in the DRC had tested positive for the virus, though no additional details about the patient’s condition or location were released.

Ihekweazu noted that his trip to Bunia revealed mixed progress: while response capacity has expanded significantly in recent weeks, systemic barriers continue to prevent teams from getting ahead of the virus. Local treatment capacity now stands at nearly 800 beds, with new spaces added every week, and laboratory testing capacity has jumped dramatically from just one operational lab at the start of the outbreak to 14 fully functional facilities. Other core response operations have also seen incremental improvements.

Still, Ihekweazu emphasized that even with these gains, response teams have not managed to overtake the virus’s spread. “Despite our best efforts … we have not caught up in the race,” he told reporters in Geneva.

The response effort has been held back by a range of interconnected challenges, including a critical shortfall in funding, repeated violent attacks on health facilities operating in the region, ongoing armed conflict that makes large parts of eastern DRC inaccessible to response teams, and widespread mistrust of medical authorities among local communities. These barriers compounded this week, when dozens of staff members at an Ebola treatment center in northeastern DRC launched a strike Monday over months of unpaid salaries and performance bonuses, further disrupting care delivery.

The Congolese government only officially declared the outbreak on May 15, after the virus had been spreading undetected through local communities for multiple weeks, the WHO confirmed. Last week, researchers finally launched long-awaited clinical trials for experimental treatments, marking the first formal effort to test targeted interventions against the current circulating strain.

What is already the fastest-expanding Ebola outbreak in recorded history is pushing response teams to their breaking point in eastern Democratic Republic of the Congo, where overlapping security, logistical and social crises have collided just as researchers launch the first clinical trial for life-saving treatments targeting this rare, untreatable strain of the virus.

The outbreak, driven by the little-studied Bundibugyo Ebola virus, a subtype with no licensed vaccines or proven treatments, has already reached a grim milestone: the DRC Ministry of Health has confirmed nearly 2,000 cases and 702 deaths to date. Worse, suspected cases have now been detected in two additional provinces, including Kisangani, one of the country’s largest urban centers, leaving responders scrambling to map the full scope of the outbreak. Experts now confirm the initial spread went undetected for weeks, as health teams initially tested for more common Ebola subtypes, and the outbreak’s zoonotic origin remains a mystery.

Unlike better-documented Ebola strains, Bundibugyo is a rare variant that spreads through direct contact with infected bodily fluids—including blood, vomit, and semen—or contact with contaminated materials such as bedding and clothing. Like other Ebola variants, it causes severe, often fatal symptoms ranging from high fever, muscle pain, vomiting and diarrhea to internal and external bleeding. Outbreaks of this strain have historically been limited to remote Central African villages near tropical rainforests, and public health guidance has restricted traditional local funeral practices that involve close contact with deceased loved ones—a measure that has sparked significant anger among local communities.

Compounding every challenge of this outbreak is the volatile, conflict-ravaged landscape where it is unfolding. Decades of violence by armed rebel groups have left local populations traumatized and deeply distrustful of outside authorities, leading to widespread misinformation that claims the Ebola outbreak is a hoax. Community outreach workers have faced threats and abuse while trying to spread prevention information, and attacks on health facilities have repeatedly disrupted response work. A portion of the outbreak is centered in Goma, a major humanitarian hub and key city that was seized by Rwanda-backed rebel forces more than a year ago, creating further barriers to coordinated relief efforts.

The latest and most urgent threat to containment efforts came this week, when unpaid frontline workers at the outbreak’s epicenter Ituri province walked off the job. The strike shuttered a core treatment center, with workers blocking access to the facility and burning tires to protest weeks of unfulfilled pay from the Congolese government, after weeks of high-risk work. Striking staff include epidemiologists, contact tracers, drivers, and gravediggers—all critical roles in stopping transmission. Congolese health officials have confirmed they are currently negotiating with workers to resolve the dispute, but public health experts warn that if the strike spreads to other overstretched, underfunded facilities across the region, it could deliver a catastrophic blow to already strained containment efforts. Infrastructure across the affected area is already extremely limited, leaving even fully staffed facilities struggling to operate.

This unrest has erupted at an exceptionally vulnerable moment for the response. Just weeks before the strike, researchers officially launched the first clinical trial for two promising experimental treatments targeting Bundibugyo Ebola, and have already begun enrolling the first participants.

The two candidate therapies are remdesivir, a broad-spectrum antiviral developed by Gilead Sciences that is already approved for COVID-19 treatment and has shown preliminary antiviral activity against Bundibugyo in laboratory testing, and MBP134, an experimental monoclonal antibody therapy developed by Mapp Biopharmaceutical that is specifically engineered to target multiple Ebola strains, including Bundibugyo.

Under the trial protocol overseen by the World Health Organization, patients will be randomly assigned to receive either the current standard of care alone, standard care plus remdesivir, standard care plus MBP134, or standard care plus both investigational treatments. The WHO has cautioned that it could take months of data collection and up to 1,000 trial participants before researchers can confirm whether either treatment is effective. Currently, the trial is only being run at one Ituri province treatment center—an unaffected facility separate from the strike site—and officials plan to expand the trial to additional sites only once security and staffing conditions allow.